在两家大型三级医疗中心使用优特克单抗引发急性输液反应的真实世界经验。
Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers.
作者信息
Spencer Elizabeth A, Kinnucan Jami, Wang Julie, Dubinsky Marla C
机构信息
Department of Pediatrics, Division of Pediatric Gastroenterology and Nutrition, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA.
出版信息
Crohns Colitis 360. 2020 Apr 10;2(2):otaa022. doi: 10.1093/crocol/otaa022. eCollection 2020 Apr.
BACKGROUND
Ustekinumab is approved for Crohn's disease and Ulcerative colitis with acute infusion reactions reported at a rate of 0.9%-4.5%.
METHODS
A retrospective chart review was conducted on inflammatory bowel disease (IBD) patients experiencing an acute infusion reaction to ustekinumab at 2 large institutions.
RESULTS
Acute ustekinumab infusion reactions occurred in 16 patients with Crohn's disease (CD) and Ulcerative colitis (UC), at a rate of 0.8%-3%. Patients were all naïve to ustekinumab, receiving their initial IV induction. Ninety-three percent subsequently tolerated the injection without issues.
CONCLUSIONS
In this large, real-world study of acute infusion reactions to ustekinumab, the rate was similar to that seen in clinical trials-0.8%-3%.
背景
优特克单抗被批准用于治疗克罗恩病和溃疡性结肠炎，急性输注反应的报告发生率为0.9%-4.5%。
方法
对两家大型机构中对优特克单抗发生急性输注反应的炎症性肠病（IBD）患者进行回顾性病历审查。
结果
16例克罗恩病（CD）和溃疡性结肠炎（UC）患者发生了优特克单抗急性输注反应，发生率为0.8%-3%。所有患者均为初次使用优特克单抗，接受首次静脉诱导治疗。93%的患者随后耐受注射且无问题。
结论
在这项关于优特克单抗急性输注反应的大型真实世界研究中，该反应发生率与临床试验中观察到的0.8%-3%相似。
Zotero 插件